EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates



Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates



Thrombosis and Haemostasis 71(5): 544-547



Very-high-purity Factor VIII concentrates produced by monoclonal or recombinant technology have been postulated to be more antigenic resulting in an increased risk of inhibitor development in hemophilia A patients. However, previous reports, mainly based on prevalence figures, may have underestimated the "true" risk of this complication in patients treated with less pure Factor VIII concentrates. The present study, started in 1975, has been designed to calculate the risk of inhibitor development in patients with severe or moderate hemophilia A. followed since their first exposure to intermediate or high-purity Factor VIII concentrates, produced by conventional technologies. Sixty-four hemophiliacs fulfilled the enrollment criteria. Inhibitors developed in 20.3% (13/64) of all patients and in 23% (11/48) of those with severe Factor VIII deficiency. Eleven patients manifested a strong anamnestic response after exposure to Factor VIII (high responders) and 2 had low inhibitor concentrations despite repeated Factor VIII infusions (low responders). The incidence of inhibitor development was 24.6 per 1000 patient-years of observation. The cumulative risk of inhibitor formation was 19.9% at age of 6 years, and 20.3% at 5 years after the first exposure. The risk was 19.3% at 70 days of exposure to Factor VIII concentrates, and 17.2% after a total of 50,000 units of Factor VIII given. Further studies are needed to confirm the above risk of acquiring an inhibitor, which indicates an under-estimation by previous studies. In addition. more data is needed to demonstrate whether very-high purity Factor VIII concentrates may be more antigenic than conventional preparations.

(PDF emailed within 1 workday: $29.90)

Accession: 008845580

Download citation: RISBibTeXText

PMID: 8091377



Related references

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010

Incidence of Factor VII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate. Thrombosis & Haemostasis 73(2): 215-218, 1995

Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999

Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. American Journal of Hematology 24(3): 241-245, 1987

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014

Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Haemophilia 4(1): 21-24, 1999

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88(6): Erep05-Erep05, 2003

Comparison of the detectability of UBOs in Neurofibromatosis Type I patients with proton density-weighted and FLAIR sequences in 3T MRI. European Journal of Paediatric Neurology, 2018

Incidence of factor VIII inhibitor development in previously untreated hemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Annals of Hematology 78(SUPPL 1): A10, 1999

Recovery and half life of factor viii coagulant activity and coagulant antigen after administration of heat treated steam treated and cold sterilized high purity factor viii concentrates in hemophilia a patients comparison of five factor viii assays. Ricerca in Clinica e in Laboratorio 16(1): 219, 1986

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates. Vox Sanguinis 77 Suppl 1: 3-8, 1999

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98(13): 3600-3606, 2001

Factor viii pro coagulant activity and factor viii pro coagulant antigen response in patients with hemophilia a and von willebrands disease after administration of different factor viii concentrates or plasma. British Journal of Haematology 47(4): 587-596, 1981